Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA registry study

  • Ayala, Rosa
  • Carreño-Tarragona, Gonzalo
  • Barragán, Eva
  • Boluda, Blanca
  • Larráyoz, María José
  • Chillón, María Carmen
  • Carrillo-Cruz, Estrella
  • Bilbao, Cristina
  • Sánchez-García, Joaquín
  • Bernal del Castillo, Teresa
  • Martínez-Cuadrón, David
  • Gil, Cristina
  • Serrano, Josefina
  • Rodríguez-Medina, Carlos
  • Bergua, Juan
  • Pérez-Simón, José A.
  • Calbacho, María
  • Alonso-Domínguez, Juan M.
  • Labrador, Jorge
  • Tormo, Mar
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Rapado, Inmaculada
  • Sargas, Claudia
  • Vázquez Urio, Iria
  • Calasanz, María José
  • Gómez-Casares, Teresa
  • García-Sanz, Ramón
  • Sanz, Miguel A.
  • Martínez-López, Joaquín
  • Montesinos, Pau
FLT3-ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3-ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3-ITD mutations. In multivariate analyses, patients with an FLT3-ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3-ITD-mutated patients, median OS gradually decreased according to FLT3-ITD status and ratio (34.3 months FLT3-ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3-ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3-ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3-ITD status in all patients, and we found that the group of FLT3-ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3-ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3-ITD mutations., We thank all patients for agreeing to participate in these studies. This study was funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01518 and PI19/00730 and co-funded by the European Union, the CRIS Against Cancer Foundation, grant 2018/001, and by the Instituto de Investigación Hospital 12 de Octubre (IMAS12). A complete list of the institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia and acute promyelocytic leukemia appears in the Supplementary Material.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry

  • Prados de la Torre, Esther
  • Serrano, Josefina
  • Barragán, Eva
  • Ayala, Rosa
  • Calasanz, María José
  • Chillón, María Carmen
  • Soria, Elena
  • Bilbao-Sieyro, Cristina
  • Cabello, Ana
  • Lavilla-Rubira, Esperanza
  • Almela Gallego, Ágata
  • Labrador Gómez, Jorge
  • Pérez-Simón, José A.
  • Rodríguez-Veiga, Rebeca
  • Martínez-Cuadrón, David
  • Vives, Susana
  • Bergua-Burgues, Juan Miguel
  • Ibañez Alis, Francisco
  • Gil, Cristina
  • Algarra, Lorenzo
  • Castaño, Tamara
  • Tormo, Mar
  • Bernal del Castillo, Teresa
  • Martínez Sánchez, María Del Pilar
  • Casado, Marisol
  • Arce Fernández, Olga
  • Herrera-Puente, Pilar
  • Vidriales Vicente, María Belén
  • Colorado, Mercedes
  • Madrigal Toscano, María Dolores
  • González, Bernardo Javier
  • Panero Ruiz, Miriam
  • Olave Rubio, Maite
  • Sánchez-García, Joaquín
  • Montesinos, Pau
The aim of our study was to analyze the incidence, co-mutation pattern, and prognostic impact of CEBPA gene mutations in a large multicenter consecutive series of 1367 adult patients AML patients treated with non-IT modalities. A total of 83 patients (6.1%) had mutations in CEBPA gene. Among these, 34 (2.5%) harbored mutations located in bZIP domain (bZIP in-frame N = 6) and 49 (3.6%) in other regions of the gene (other CEBPAmut). Genes most frequently co-mutated in these CEBPAmut patients were TET2 (45.8%, N = 38), SRSF2 (42.2%, N = 35), and ASXL1 (40.9%, N = 34). Using the Bradley-Terry model we identified that mutations in MDS-related genes, in TP53, and in epigenetic regulators appear to occur earlier. In contrast, genes involved in activating cell signaling appeared to occur later than CEBPAmut. Overall Survival (OS) of non-IT AML patients was analyzed according to the type of CEBPAmut. Median OS was 11.6 months in CEBPA-bZIP patients compared to 9.0 and 6.9 for patients with other CEBPAmut or CEBPAwt, respectively. When selecting 1129 AML patients treated with HMA or HMA-based combinations, CEBPA-bZIP patients had a median survival time of 11.6 months (range 9.6-NR) and 2.5 years survival probability of 20.1% which were outcomes comparable to remaining ELN2024 favorable patients. We concluded that our series of non-IT AML patients within the PETHEMA registry confirm a low percentage of CEBPA mutated cases which are frequently co-mutated with MDS related genes. Those CEBPA-bZIP cases harbor a similar median OS than those belonging to favorable ELN2024 risk category., This investigation was partially supported by Instituto de Salud Carlos III, Spain, grant PMP22/00069 and PI19/00730., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

  • Ayala, Rosa|||0000-0002-2699-8353
  • Rapado, Inmaculada
  • Onecha, Esther
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Algarra Algarra, Jesus Lorenzo
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Herrera, Pilar|||0000-0002-4118-7110
  • Ramos, Fernando
  • Salamero, Olga|||0000-0003-3237-0025
  • Lavilla, Esperanza|||0000-0003-1490-0678
  • Gil, Cristina
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Vidriales, María Belén|||0000-0001-5049-3673
  • Labrador, Jorge|||0000-0002-3696-0287
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Sayas, María José
  • Paiva, Bruno|||0000-0003-1977-3815
  • Barragán, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Montesinos, Pau|||0000-0002-3275-5593
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 -7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.